One Touch® Verio®IQ European Clinical Outcomes Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01631643
Recruitment Status :
(Business decision to withdraw trial)
Evaluation of the clinical benefits of One Touch VerioIQ system.
Condition or disease
Device: One Touch VerioIQ Blood Glucose Monitor
Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
male or female at least 18 to 80 years old
ADA guidelines for FPG and PPG appropriate
A1C greater or equal to 8.0% and less than or equal to 10.5%
lab A1C greater than or equal to 8.0% in the last 6-12mths
Diagnosed with type 1 or 2 in at least last 1 year
on stable dose of OADs for at least 3mths prior to screening
willingness to test 7 BGM tests per day
willing to remain on same therapy as baseline (MDI) for duration of study